MedPath

Electronic Cardiac Rehabilitation (eCardiacRehab) Feasibility Study

Not Applicable
Recruiting
Conditions
Coronary Artery Disease
Cardiac Rehabilitation
Ethics
Continuity of Patient Care
Older Adults (65 Years and Older)
Cost-Benefit Analysis
Adherence, Medication
Adherence, Treatment
Health Literacy
EHealth Literacy
Registration Number
NCT06759805
Lead Sponsor
Haukeland University Hospital
Brief Summary

In Norway, more than 11,000 patients undergo percutaneous coronary intervention (PCI) annually. However, a very recent study utilizing registry data show a national average of cardiac rehabilitation (CR) participation of only 14%, despite its proven beneficial effects on readmissions, physical capacity, psychological distress, self-management, and quality of life. CR is strongly recommended in European guidelines. However, uptake is low and is not systematically identifying those in most need of CR. The primary objective of eCardiacRehab is to meet rehabilitation needs of large patient populations regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based eCardiacRehab programme. eCardiacRehab address patient- and system level challenges in order to increase access to CR. The investigators give particular attention to older patients, women, and those with comorbidities or mental health challenges. Aspects related to continuity of care between specialist and primary care services, health literacy, adherence to treatment, cost effectiveness and ethics are investigated. The investigators will 1) continue to develop the programme with patients, general practitioners, healthcare experts from both specialist and primary care services, and technology developers, 2) develop treatment modules, 3) establish information and communication infrastructure, 4) evaluate the process and efficacy of treatment modules, 5) ensure knowledge development and transfer of competence to the municipalities, and 6) contribute to fulfil the innovation potential for health service and industry partners. eCardiacRehab has the potential to improve interaction and collaboration between primary and secondary care, modernise and digitalise work processes, and develop more coherent and tailored patient pathways. The vision of the home-based eCardiacRehab is to make CR available to all.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number,
  • With coronary artery disease after percutaneous coronary intervention
  • Are living at home and have internet available to them
  • Providing signed informed consent
Exclusion Criteria
  • Patients with cognitive impairment that may interfere with the ability to comply with the study protocol
  • Severe aortic stenosis
  • Severe arrhythmias
  • Expected lifetime less than one year as determined by study personnel
  • Otherwise clinically unstable
  • Not fully revascularized (awaits percutaneous coronary intervention or coronary artery bypass graft surgery)
  • Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The participants' engagement and adherence to the interventionFrom start to the end of the programme (12 weeks)

Based on previous studies, the success criteria will be one login to the website on average once per week, and that 50% of participants will watch some or all the video messages on the website. Usage will be assessed as time spent using the programme, number of logins with start and end time, summary of number of sessions, messages sent, modules completed, and registrations per patient, number of completed questionnaires per patient, and start and end time for all modules in the programme. This will be assessed based on website usage statistics gathered by a website visit tracking system. Further, participants will be asked to report login-errors.

Missing rateFrom start to end of programme (12 weeks)

Acceptability of the secondary and primary outcomes is assessed through response and completion rates. The proportion of missing data in each completed questionnaire at baseline and at the end of the intervention of less than 20% is acceptable.

Attrition rateFrom start to the end of programme (12 weeks)

A success criterion to reduce the threats to validity is an attrition rate of no more than 20%. When possible, the reasons for participants leaving the study are obtained and reported in a study log.

Secondary Outcome Measures
NameTimeMethod
Hospitalization180 days hospitalization

Composite end-point of Emergency Department (ED) contact and home, ED and observation, ED and admission (\>24 hours), and death, whichever comes first.

Change in beliefs and perceptions about medicines and treatmentUp to 24 months.

The Beliefs about Medicines Questionnaire (BMQ) assesses beliefs and perceptions about medicines and treatment. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. The two sections of the BMQ can be used in combination or separately. For this study, the BMQ-Specific will be used. Respondents rate 11 items on a 5-point scale ranging from 1 (strongly agree) to 5 (strongly disagree).

Continuity of careSelf-report up to 6 months.

The Heart Continuity of Care Questionnaire (HCCQ) comprises 33 items covering eight topic areas regarding continuity of care. Respondents rate each item on a 6-point scale ranging from 1 (strongly disagree) to 5 (strongly agree) or 6 (not applicable).

Change in health literacyUp to 24 months

The Health literacy questionnaire (HLQ) has nine scale scores that each measure an aspect of the multidimensional construct of health literacy. Each score provides insight into the strengths and limitations of the respondent, but the scores are most powerful when viewed together to show the 'health literacy profile' of the respondent

Anxiety and depressionUp to 24 months

The Hospital Anxiety and Depression Scale (HADS). The HADS is a fourteen item scale where seven of the items relate to anxiety and seven relate to depression. The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). The total score is 42 (21 per subscale).

Maximal oxygen consumption (Vo2 max)Baseline and 12 weeks.

Maximal oxygen consumption (VO2max) as measured by cardiopulmonary exercise testing (CPET).

Healthcare utilizationUp to 24 months.

Healthcare utilization will be assessed during follow-up, including patients' use of primary care services (general practitioner visits) and secondary care services (inpatient admissions and outpatient visits). The data source will be nationwide registries. The measurement unit will be mean number of visits.

Healthcare costUp to 24 months.

Health care (associated) costs will be valued using the tariffs of national agreements between the professional associations of medical specialists and the National Health Services. In secondary care, inpatient admissions and outpatient visits will be valued using the tariffs of the national case-mix system of the diagnosis-related groupings (DRG) and the ambulatory grouping system (DAGS). In addition, data will be collected on prescription of medication, which will be valued using the retail price. The data source will be nationwide registries. The measurement unit will be mean costs in Euros.

Change in health status following myocardial infarctionUp to 24 months.

The Myocardial Infarction Dimensional Assessment Scale (MIDAS) is a PRO measure developed and validated to specifically measure the health status of individuals who have suffered a myocardial infarction. It consist of 7 domains, and is a 35 item scale where respondents rate each item on a 5-point scale ranging from 1 (never) to 5 (always). The function of the MIDAS is to indicate the extent of ill health in each of the seven domains assessed, therefore each dimension is scored separately using a simple scoring methodology.

Change in fatigueUp to 24 months

A visual analog scale ranging from 0 (fatigue is not a problem) to 10 (fatigue is a major problem) is used to measure change in fatigue.

Change in eHealth literacyUp to 24 months

The eHealth Literacy Scale (Eheals) is an 8-item measure of eHealth literacy developed to measure consumers' combined knowledge, comfort, and perceived skills at finding, evaluating, and applying electronic health information to health problems. Respondents indicate their agreement with statements on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly agree).

Change in medication useUp to 10 years

Data related to consumption of prescribed medication are identified through national prescription registries. The registries cover all prescriptions dispensed at pharmacies nationwide. The registries also include information about date of dispensation, quantity and strength dispensed. This will serve as complimentary information to patients' self-reported adherence.

Change in physical and mental dimensions of healthUp to 24 months

RAND-12 measures physical and mental dimensions of health. The 12 items in the questionnaire correspond to eight principal physical and mental health domains. The 12 items are summarized into two scores, a "Physical Health Summary Measure (PCS-physical component score)" and a "Mental Health Summary Measure (MCS-mental component score)".

Health related quality of lifeUp to 24 months

The HeartQoL questionnaire is a core ischemic heart disease specific health related quality of life (HRQL) questionnaire. The questionnaire comprises 14-items with 10-item physical and 4-item emotional subscales which are scored from 0 (poor HRQL) to 3 (better HRQL) with a global score if needed.

Medication adherence assessed by therapeutic drug monitoringBaseline, 3 and 6 months

Serum levels of cardiac medications (quantified using liquid chromatography with mass spectrometry)

Change in self-reported medication adherenceUp to 24 months

The my experience of taking medicines (MYMEDS) questionnaire consists of six sections. Section 1: essential contextual information (e.g. the medicines taken). Section 2: overall understanding and satisfaction with medicines (four-point Likert scale (strongly agree, agree, disagree, strongly disagree)). Section 3: areas of anxiety about medicines (e.g. worry that they will cause more harm than good). Section 4: four separate practical concerns associated with medicines taking (e.g. swallowing problems). Section 5: assesses three issues in fitting medicines into patients' daily routine (e.g. relating to forgetfulness or inconvenience). Section 6: asks about adherence to each individual medicine over the past month (five point Likert scale). .

Change in chest painUp to 24 months

The Seattle Angina Questionnaire (SAQ-7) comprises 7 dimensions of coronary artery disease. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).

Change in self-reported healthUp to 24 months

EQ-5D-5L is an 5 item (plus a VAS scale) self-report-questionnaire assessing self-reported health. Each question has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

Digital health readinessUp to 24 months

Responses to the Digital Health Readiness Questionnaire (DHRQ) are scored on a 5-point Likert scale (strongly disagree to strongly agree). The sum of the first 4 domains gives the total score on the DHRQ. The minimum score of the DHRQ is 15, and the maximum score of the DHRQ is 75. Additionally, a fifth domain called digital learnability is assessed.

Change in insomniaUp to 24 months

The Minimal Insomnia Symptom Scale (MISS) comprises 3 items assessing major features of insomnia, i.e. difficulties initiating sleep, waking at night and not feeling refreshed by sleep.

Change in sleepUp to 24 months

The Sleep Sufficient Index (SSI) comprises 2 items assessing amount of actual and desired sleep.

Blood samplesBaseline, 3 and 6 months.

HbA1c (≤7.0%), lipids, cardiac and inflammation markers(e.g. troponins, natriuretic peptides and CRP).

Change in blood pressureUp to end of programme

Blood pressure targets (\<120/70 mmHg at nurse visit; \<120/70 mmHg at home measurement)

Change in biometricsBaseline, start and end of programme

BMI (WHO- classification), visceral fat, muscle mass, body fat.

Change in nicotine statusUp to 24 months

Self-reported change in nicotine status

Change in self-reported intensity-adjusted minutesUp to 24 months

The the physical activity frequency, intensity, and duration (PAFID) questionnaire contains three items on physical activity: (i) frequency \[never (0), less than once per week (0.5), once per week (1), 2-3 times per week (2.5), or almost every day (5)\]; (ii) duration of each exercise session \[\<15 min (7.5), 15-29 min (22.5), 30-60 min (45), or over 60 min (75)\]; and (iii) intensity \[low ('I take it easy, I don't get out of breath or break a sweat'), moderate ('I push myself until I'm out of breath or break into a sweat'), or high ('I practically exhaust myself')\]. The number of minutes of physical activity is calculated as the average time spent per session multiplied by the average frequency of exercise per week multiplied by the weighted intensity \[low (0.5), moderate (1), and high (2)\] based on the values in brackets.

Biosensor dataThroughout the 12-week program

Biosensor data is collected throughout the 12-week program, and include time spent sedentary and in light-, moderate- and vigorous-intensity physical activity, daily step count, resting/maximal heart rate, sleep time and quality and time and duration of wearing the wearable device.

Trial Locations

Locations (1)

Haukeland University Hospital

🇳🇴

Bergen, Norway

© Copyright 2025. All Rights Reserved by MedPath